CA-VISA
Visa (NYSE:V) today announced it has further expanded its support of women’s football by becoming the first Women’s Football Partner for the FIFA Women’s World Cup 2023™. This investment builds on long-term commitments Visa has made across Europe and around the world, to help elevate women’s football and usher in greater equality within the sport.
“Women are a force to be reckoned with – on the pitch, as small business owners, and as drivers of a majority of consumer purchases. We know that when we support the success of women in sport, we support the success of women everywhere,” said Lynne Biggar, Chief Marketing Officer, Visa. “Becoming the first FIFA Women’s Football Partner is part of a much larger investment in women’s initiatives to help recognize the limitless potential of women around the world.”
Visa is one of the world’s most active sponsors of women’s football. Through the company’s sponsorship of the FIFA Women's World Cup 2023™ and other leading women’s football organizations around the world, the company strives to be a catalyst for change and contribute to the growing recognition of women’s football. The FIFA Women's World Cup 2019™ tournament was watched by a record 1.12 billion viewers1 and marked Visa’s largest onsite investment in women’s football, providing the latest payment technology at all venues and curating exclusive experiences for consumers and clients from around the world.
As the FIFA Women’s World Cup™ heads to Australia and New Zealand in 2023, marking the first time the Tournament will be played across two countries and be expanded to 32 teams, Visa will enable similar one-of-a-kind experiences for football fans globally, activate the Player of the Match award and incorporate its Team Visa program for women footballers. Additionally, as the Exclusive Payment Service for the FIFA Women’s World Cup 2023™, Visa will implement its innovative payment technology at tournament venues and deliver exclusive experiences for fans and clients, ranging from delivering innovative ways to pay to utilizing Visa’s exclusive marketing campaign assets to drive mutual business priorities with clients.
“As a long-standing FIFA Partner and a proud supporter of women’s football, it was a natural choice for Visa to become the first ever Women’s Football Partner at FIFA,” said Sarai Bareman, FIFA’s Chief Women’s Football Officer. “Visa is well known for supporting athletes and seeing the positive benefits that can come through sport. They are advocates for equality, diversity, and inclusion, core values that are shared by FIFA and the FIFA Women’s World Cup, as we grow and celebrate the women’s game.”
Given the correlation between success in sport and business – 94% of women in the C-suite have played a sport at some time in their lives2 – Visa’s support for women does not end on the pitch. Visa continues to develop programs that open more opportunities for women on and off the field:
- Team Visa: Designed to help athletes succeed in their athletic career and beyond, Team Visa has championed more than 500 athletes since its inception. Of those athletes, 55% are women, including 22 female footballers such as Lucy Bronze (England), Alexia Putellas (Spain) and Ellie Carpenter (Australia).
- The Second Half: Launched in the UK in early 2021, the Second Half is a Visa career development program to support female footballers as they consider careers beyond football. The program helps women recognize how to translate the skills they have developed – perseverance, teamwork, and commitment – outside of sport.
- She’s Next, Empowered by Visa: Broader Visa programs – such as She’s Next – support women entrepreneurs around the world and work to close gaps with educational tools, mentorship and meaningful funding.
“I love having the opportunity to encourage young people to chase their dreams and am so proud to be part of Team Visa because the company shares this same vision and supports what I do,” said Ellie Carpenter, defender on Australia’s national women’s football team. “To be looking ahead toward playing the FIFA Women’s World Cup 2023™ in my home country is an absolute dream come true.”
Visa’s first-ever sponsorship of the FIFA Women’s World Cup 2023™ complements its global investment in women’s football , including its ground-breaking partnership with UEFA Women’s Football, and sponsorship of the U.S. Soccer Federation, including the U.S. Women’s National Team and the SheBelieves Cup. It also builds on Visa’s longstanding partnership with FIFA, including the FIFA World Cup™, FIFA Women's World Cup™ and other FIFA events.
About Visa Inc.
Visa (NYSE: V) is a world leader in digital payments, facilitating more than 215 billion payments transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories each year. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com
.
____________________
1
FIFA
, October 2019
2
EY, “Why a Female Athlete Should Be Your Next Leader”
, September 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005151/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom